Inhaled Cannabis
Participants will receive inhaled cannabis and placebo
Loading study record…
Loading study record…
This inpatient study enrolls healthy individuals who have opioid use disorder. Participants live at the University of Kentucky Hospital for approx. 6 weeks. During this time, we will examine how repeated doses of oral cannabis and acute doses of oral and inhaled cannabis 1) modify the intensity and time course of opioid withdrawal, 2) modify the effects of intranasal opioid administration and 3) impact the safety of opioid administration.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2026-08-20
What this record can show
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Interventions
Participants will receive inhaled cannabis and placebo
Participants will receive intranasal opioids and placebo
Eligibility
primary outcomes
Time frame: This outcome will be assessed regularly from baseline through 6 hours post cannabis dose during experimental sessions.
Opioid severity is a participant-rated outcome that will be measured on a visual analog scale (0-100)
Publications
No exact PMID-linked public article is currently readable locally.